BAM
RXRX icon

Brave Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Brave Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,433
Closed -$46.8K – 176
2025
Q4 		$46.8K Hold
11,433
– – 0.01% 158
2025
Q3 		$55.8K Hold
11,433
– – 0.01% 162
2025
Q2 		$57.9K Hold
11,433
– – 0.02% 154
2025
Q1 		$60.5K Hold
11,433
– – 0.02% 146
2024
Q4 		$77.3K Buy
11,433
+1,433
+14% +$9.63K 0.02% 147
2024
Q3 		$65.9K Hold
10,000
– – 0.02% 153
2024
Q2 		$75K Hold
10,000
– – 0.02% 140
2024
Q1 		$99.7K Sell
10,000
-5,000
-33% -$55.7K 0.03% 142
2023
Q4 		$148K Buy
+15,000
New +$107K 0.04% 133

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Brave Asset Management's RXRX Position: Q1 2026 in Review

Brave Asset Management sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 11,433 shares — an estimated $46.8K sold.

Brave Asset Management first reported a position in RXRX in Q4 2023 and held it in 9 quarters. The position peaked at $148K in Q4 2023. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Brave Asset Management reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Brave Asset Management sold 11,433 Recursion Pharmaceuticals shares in Q1 2026, an estimated $46.8K.
  • Brave Asset Management first reported a position in Recursion Pharmaceuticals in Q4 2023 and held it in 9 quarters.
  • Brave Asset Management's Recursion Pharmaceuticals position peaked at $148K in Q4 2023.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Brave Asset Management's 13F filing for Q1 2026, filed 17 Apr 2026.